Evaluation of the correlation between cytoplasmatic ATOX1 levels and patient outcome after TM treatment for the different stages of disease demonstrated that the patients who were diagnosed at disease stage III, and not at disease stage IV, had a significantly better EFS when having high ATOX1 levels in their tumor. Here, ATOX1 is linked to neoplasm.